Cargando…

A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria

Treatment of paroxysmal nocturnal haemoglobinuria (PNH) includes the monoclonal antibody eculizumab. This randomised, double‐blind, multi‐national cross‐over Phase III study in PNH patients aimed to demonstrate the equivalence of the proposed eculizumab biosimilar SB12 and reference eculizumab (Soli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Jun Ho, Gomez, Roberta Demichelis, Bumbea, Horia, Nogaieva, Larysa, Wong, Lily Lee Lee, Lim, Soo Min, Kim, Younsoo, Park, Jihye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Sickle Cell, Thrombosis, and Classical Haematology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928655/ https://www.ncbi.nlm.nih.gov/pubmed/36819188 http://dx.doi.org/10.1002/jha2.632

Ejemplares similares

P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Jang, J. H., et al.
Publicado: (2022)

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria
por: Gaya, Anna, et al.
Publicado: (2023)

Paroxysmal nocturnal haemoglobinuria, diagnosis and haematological findings, first report from Iran, model for developing countries
por: Jahangirpour, Mohammadali, et al.
Publicado: (2022)

Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
por: Adhikari, Sugat, et al.
Publicado: (2023)

Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria
por: Eliesen, Gaby A.M., et al.
Publicado: (2020)

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
por: Socié, Gérard, et al.
Publicado: (2019)

Acute kidney injury in Jamaicans with sickle cell disease hospitalized with COVID‐19 infection
por: Fisher, Lori‐Ann, et al.
Publicado: (2023)

Impact of age‐dependent red blood cell parameters on α‐globin gene genotyping in children
por: Nissen, Peter H., et al.
Publicado: (2022)

Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

SARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity
por: Toomer, Kevin H., et al.
Publicado: (2023)

Red blood cell alloantibodies in paediatric transfusion in sub‐Saharan Africa: A new cohort and literature review
por: Gadji, Macoura, et al.
Publicado: (2023)

Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies
por: Shields, Adrian M., et al.
Publicado: (2023)

Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States
por: Cuker, Adam, et al.
Publicado: (2023)

Family planning needs of young adults with sickle cell disease
por: Linton, Elizabeth A., et al.
Publicado: (2023)

Real‐world complication burden and disease management paradigms in transfusion‐related β‐thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross‐sectional study
por: Kattamis, Antonis, et al.
Publicado: (2023)

Unsupervised machine learning algorithms identify expected haemorrhage relationships but define unexplained coagulation profiles mapping to thrombotic phenotypes in hereditary haemorrhagic telangiectasia
por: Mukhtar, Ghazel, et al.
Publicado: (2023)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Comparative analysis of opioid use in sickle cell crisis in an urban facility in Ghana
por: Opoku‐Agyakwa, Marian, et al.
Publicado: (2023)

Clinical and haematological characteristics of 38 individuals with Hb G‐Makassar in Malaysia
por: Esa, Ezalia, et al.
Publicado: (2023)

Impact of COVID‐19 on incidence, clinical presentation, and prognosis of acute chest syndrome in patients with sickle cell disease
por: Dubois, Gabin, et al.
Publicado: (2023)

Sickle cell anemia and pregnancy: Profile of hemodynamic changes in sickle cell pregnant women in Kinshasa
por: Mikobi, Tite Minga, et al.
Publicado: (2023)

HLA haplotype frequencies and diversity in patients with hemoglobinopathies
por: Scigliuolo, Graziana M., et al.
Publicado: (2023)

Empowering patients with sickle cell anemia and their families through innovative educational methods
por: Plett, Riley, et al.
Publicado: (2023)

Disease knowledge and health literacy in parents of children with sickle cell disease
por: Ikediashi, Bonaventure G., et al.
Publicado: (2023)

PB2051: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB
por: Lee, Hyuna, et al.
Publicado: (2023)

Eculizumab treatment for paroxysmal nocturnal haemoglobinuria in a patient with recurrent simultaneous multivessel coronary stent thrombosis
por: De Maria, Giovanni Luigi, et al.
Publicado: (2015)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects
por: Lee, Hyun A, et al.
Publicado: (2022)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
por: Al-Ani, Fatimah, et al.
Publicado: (2016)

Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
por: Fassett, Michael J., et al.
Publicado: (2021)

Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab
por: Moon, Ji Young, et al.
Publicado: (2017)

Plasma exchange for COVID‐19 thrombo‐inflammatory disease
por: Arulkumaran, Nishkantha, et al.
Publicado: (2020)

Is sickle cell disease a risk factor for severe COVID‐19 outcomes in hospitalized patients? A multicenter national retrospective cohort study
por: Abdulrahman, Abdulkarim, et al.
Publicado: (2021)

Clusters of pain trajectories among patients with sickle cell disease hospitalized for vaso‐occlusive crisis: A data‐driven approach
por: Rodday, Angie Mae, et al.
Publicado: (2020)

Patterns of healthcare utilization among patients with sickle cell disease hospitalized with pain crises
por: Rodday, Angie Mae, et al.
Publicado: (2020)

Mild anemia as a single independent predictor of mortality in patients with COVID‐19
por: Tremblay, Douglas, et al.
Publicado: (2021)

In‐hospital mortality in SARS‐CoV‐2 stratified by hemoglobin levels: A retrospective study
por: Al‐Jarallah, Mohammed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_89luqhrj7knq6hommis88hvgh8